Nurix Therapeutics NRIX
NASDAQ NRIX
$16.33 +0.45 (+2.83%)
At close: Nov 11, 2026 · 4:00 PM EST

Nurix Therapeutics (NRIX) Return on Sales [ROS] (2019 - 2026)

Updated

Nurix Therapeutics (NRIX) recorded Return on Sales [ROS] of 83.12% in fiscal Q3 2026 (quarter ended Aug 31, 2026), up 1240.77 percentage points from -1157.65% a year earlier and up 1124.85 percentage points from the prior quarter.

Analysis

Nurix Therapeutics (NRIX) Return on Sales [ROS] (2019 - 2026) Analysis & Trends

On a TTM basis, Nurix Therapeutics' Return on Sales [ROS] came in at 41.27% as of Aug 31, 2026, up 360.58 percentage points year-over-year; for FY2025 (ended Nov 30, 2025), it was -340.16%, up 50.36 percentage points from FY2024.

  • Annual Return on Sales [ROS] has a five-year change of +24.50 percentage points (FY2020 to FY2025).
  • Across earlier fiscal years, Return on Sales [ROS] came in at -390.52% in FY2024 (-189.11 pp), -201.41% in FY2023 (+274.59 pp), -476.01% in FY2022 (-79.75 pp) and -396.26% in FY2021 (-31.59 pp).
  • The fiscal Q3 2026 figure is the highest quarterly Return on Sales [ROS] in data going back to fiscal Q3 2019.
  • On a year-over-year basis, Return on Sales [ROS] rose in two of the last eight quarters, with an average year-over-year change of -205.39 percentage points.
  • Peak year-over-year performance for Return on Sales [ROS] in the last five years was a gain of 1240.77 percentage points in fiscal Q3 2026, against a drop of 1138.78 percentage points in fiscal Q1 2026 at the low end.
  • Per Business Quant, the preceding three fiscal quarters came in at -1041.73% (Q2 2026), -1479.45% (Q1 2026) and -612.03% (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 24.35%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 36.01%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 29.12%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.79%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 41.71%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 32.98%
10 Nurix Therapeutics 1.73 Bn -891.35 Mn - 83.12%
Historic Data

Historic Data

Download Data
DateValue
Aug 31, 2026 83.12%
May 31, 2026 -1,041.73%
Feb 28, 2026 -1,479.45%
Nov 30, 2025 -612.03%
Aug 31, 2025 -1,157.65%
May 31, 2025 -109.68%
Feb 28, 2025 -340.67%
Nov 30, 2024 -486.73%
Aug 31, 2024 -433.83%
May 31, 2024 -401.42%
Feb 29, 2024 -272.65%
Nov 30, 2023 -299.06%
Aug 31, 2023 -216.67%
May 31, 2023 -87.25%
Feb 28, 2023 -338.60%
Nov 30, 2022 -717.82%
Aug 31, 2022 -432.93%
May 31, 2022 -399.89%
Feb 28, 2022 -444.28%
Nov 30, 2021 -513.16%
API Access

Nurix Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=NRIX&period=max&api_key=YOUR_API_KEY